Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 7,009 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urologic Diseases Clear all
Completed No phase listed Observational

Oxygen Desaturation During Hemodialysis

NCT02501044
View directory record Official record
Conditions
Renal Disease, Hypoxia
Interventions
Not listed
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years and older
Enrollment
5,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 17, 2026, 4:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Vaginal and Urinary Microbiome Trial

NCT02869165
View directory record Official record
Conditions
Atrophic Vaginitis, Menopause, Recurrent Urinary Tract Infections
Interventions
Conjugated equine estrogen topical cream, Apricot kernel oil
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 17, 2026, 4:28 AM EDT
Completed Not applicable Interventional Results available

Pilot Study to Evaluate Safety, Tolerability, and Performance of the FAST PV Technology™ in Chronic Dialysis Patients

NCT04733664
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
VFI using the FAST PV Technology
Device
Lead sponsor
FAST BioMedical
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 17, 2026, 4:28 AM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

NCT02635672
View directory record Official record
Conditions
Neoplasms
Interventions
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 17, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

Losartan to Reverse Sickle Nephropathy

NCT01479439
View directory record Official record
Conditions
Nephropathy, Sickle Cell Anemia
Interventions
Losartan
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Chicago, Illinois • Louisville, Kentucky • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 17, 2026, 4:28 AM EDT
Completed Phase 1 Interventional Results available

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

NCT02833857
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Louisville, Kentucky • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 17, 2026, 4:28 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

NCT06557265
View directory record Official record
Conditions
Lupus Nephritis, Primary Membranous Nephropathy
Interventions
NKX019, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Nkarta, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Little Rock, Arkansas • Tustin, California • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 17, 2026, 4:28 AM EDT
Completed Phase 2 Interventional

Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder

NCT00136175
View directory record Official record
Conditions
Bladder Cancer
Interventions
Paclitaxel, Carboplatin, Gemcitabine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 17, 2026, 4:28 AM EDT
Not listed Phase 3 Interventional

The Use of Nesiritide in Thoracic Aneurysm Repair to Prevent Acute Renal Failure

NCT00110201
View directory record Official record
Conditions
Cardiovascular Disease, Acute Renal Failure, Death
Interventions
Nesiritide
Drug
Lead sponsor
Ejaz, Abulate A, MD
Individual
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 4:28 AM EDT
Recruiting Phase 4 Interventional

Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

NCT06110130
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Empagliflozin 10 MG, Placebo
Drug
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
19 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 17, 2026, 4:28 AM EDT
Completed No phase listed Observational

Preterm Infants and Nephrocalcinosis

NCT02438267
View directory record Official record
Conditions
Prematurity, Nephrocalcinosis, Hypercalciuria
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Up to 2 Weeks
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 17, 2026, 4:28 AM EDT
Recruiting Phase 1 Interventional

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

NCT06764771
View directory record Official record
Conditions
Advanced Malignant Tumors
Interventions
BMS-986488, Adagrasib, Cetuximab, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Hackensack, New Jersey • Allentown, Pennsylvania • Germantown, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 17, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

NCT03990363
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Verinurad, Allopurinol, Placebo for Verinurad, Placebo for Allopurinol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
861 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
54
States / cities
Huntsville, Alabama • Bakersfield, California • Canyon Country, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 17, 2026, 4:28 AM EDT
Terminated No phase listed Observational

A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma

NCT01063998
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Urine Marker
Other
Lead sponsor
Jason Hafron
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 17, 2026, 4:28 AM EDT
Completed Not applicable Interventional

Pomegranate Supplementation on Physical Function and Cardiovascular Disease Risk in CKD Patients

NCT01324193
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease
Interventions
Pomegranate extracts
Dietary Supplement
Lead sponsor
Kenneth Wilund
Other
Eligibility
30 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Champaign, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 17, 2026, 4:28 AM EDT
Withdrawn Phase 4 Interventional

Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease

NCT00584090
View directory record Official record
Conditions
Urinary Incontinence, Parkinson's Disease
Interventions
Solifenacin Succinate (VESIcare), Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
30 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 17, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

NCT02019693
View directory record Official record
Conditions
Kidney Cancer
Interventions
INC280
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 17, 2026, 4:28 AM EDT
Terminated Phase 2 Interventional Results available

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

NCT02669914
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast, Cancer of the Breast, Gastroesophageal Cancer, Pancreatic Cancer, Cancer of the Pancreas, Colorectal Cancer, Colorectal Carcinoma, Renal Cancer, Kidney Cancer, Cancer of the Kidney, Cancer of Kidney, Ovarian Cancer, Ovary Cancer, Cancer of the Ovary, Cancer of Ovary
Interventions
MEDI4736
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 17, 2026, 4:28 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

High-Intensity Interval Training and Regulatory T Cells

NCT04774484
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
High Intensity Interval Training
Other
Lead sponsor
Francesc Marti
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 17, 2026, 4:28 AM EDT
Active, not recruiting Phase 2 Interventional

Bladder Directed vs. Pelvic Floor Therapy in IC/BPS

NCT02870738
View directory record Official record
Conditions
Cystitis, Interstitial, Painful Bladder Syndrome
Interventions
Pelvic Floor Physical Therapy, Bladder Instillations
Procedure · Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 17, 2026, 4:28 AM EDT
Available No phase listed Expanded access

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

NCT06443944
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Urologic Cancer, Bladder Cancer
Interventions
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
Drug · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
27
States / cities
Gilbert, Arizona • Bakersfield, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 17, 2026, 4:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

NCT02134314
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions
C1 Esterase Inhibitor, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 17, 2026, 4:28 AM EDT
Recruiting Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

NCT06717698
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
NNC0519-0130, Placebo, Semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
18
States / cities
San Dimas, California • San Ramon, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 17, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Results available

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)

NCT00598806
View directory record Official record
Conditions
Bladder Cancer
Interventions
Apaziquone, Placebo, TURBT
Drug · Procedure
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
21
States / cities
Anaheim, California • West Palm Beach, Florida • Marietta, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 17, 2026, 4:28 AM EDT